Manuel Baca, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute
Dafna Bar-Sagi, PhD
Executive Vice President, Chief Scientific Officer, NYU Grossman School of Medicine
Peter Meinke, PhD
Director, Tri-Institutional Therapeutics Discovery Institute
David Morrissey, PhD
VP, Head RNA Accelerator, Pfizer
Marilyn Resh, PhD
Member Emeritus, Sloan Kettering Institute
Joseph Scandura, MD, PhD
Scientific Director, Richard T. Silver MPN Center, Weill Cornell Medical College
Manuel Baca, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute
Craig Crews, PhD
Executive Director, Yale Center for Molecular Discovery
Barbara Hempstead, MD, PhD
Dean, Weill Cornell Graduate School of Medical Sciences
Tarun Kapoor, PhD
Professor, Rockefeller University
Peter Meinke, PhD
Director, Tri-Institutional Therapeutics Discovery Institute
Dafna Bar-Sagi, PhD
Senior Vice President, Vice Dean for Science, and Chief Scientific Officer, New York University School of Medicine
Catherine Bollard, MD
Director, Center for Cancer and Immunology Research, Children’s Research Institute, Children’s National Health System
Katherine High, MD
Co-Founder, President, and Head of R&D, Spark Therapeutics Inc.
Ivo Lorenz, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute
Joseph Scandura, MD, PhD
Scientific Director, Richard T. Silver MPN Center, Weill Cornell Medicine
Edward Skolnik, MD
Professor, Medicine and Biochemistry and Molecular Pharmacology, New York University School of Medicine
Michael Foley, PhD
Director, Tri-Institutional Therapeutics Discovery Institute
Ivo Lorenz, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute
Gary Schwartz, MD
Deputy Director, Herbert Irving Comprehensive Cancer Center
Edward Skolnik, MD
Director, Division of Nephrology, New York University Langone Medical Center
Neil Stahl, PhD
Executive Vice President, Research and Development, Regeneron Pharmaceuticals
Michael Foley, PhD
Director, Tri-Institutional Therapeutics Discovery Institute
Hyam Levitsky, MD
Executive Vice President and Chief Scientific Officer, Juno Therapeutics
Ivo Lorenz, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute
David Nanus, MD
Chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine
Benjamin Neel, MD, PhD
Director, Laura and Isaac Perlmutter Cancer Center, New York University
Michael Foley, PhD
Director, Tri-Institutional Therapeutics Discovery Institute
Angus Grant, PhD
Corporate Vice President, Business Development, Celgene
Ivo Lorenz, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute
David Nanus, MD
Chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine
Benjamin Neel, MD, PhD
Director, Laura and Isaac Perlmutter Cancer Center, New York University
Juan Harrison
Vice President, Takeda Ventures, Inc.
Nils Lonberg, PhD
Senior Vice President, Immuno-Oncology & Biologics Discovery, Bristol-Myers Squibb
Jeffrey Molldrem, MD
Chief, Section of Transplantation Immunology, Dept. of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center
John Porco, PhD
Director, Chemical Methodology and Library Development Center, Boston University
Michael Foley, PhD
Tri-Institutional Therapeutics Discovery Institute
Thorsten Graef, MD, PhD
Pharmacyclics
Garth Powis, DPhil
Sanford Burnham Medical Research Institute
Raymond Warrell, MD
Relburn-Metabolomics
Jeffrey Aubé, PhD
University of Kansas
Michael Foley, PhD
Broad Institute of MIT and Harvard
Frank Haluska, MD, PhD
Ariad Pharmaceuticals
Raymond Warrell, MD
Relburn
Jeffrey Aubé, PhD
University of Kansas
José Baselga, MD, PhD
Massachusetts General Hospital Cancer Center
Michael Foley, PhD
Broad Institute of MIT and Harvard
Richard van Etten, MD, PhD
Tufts Medical Center Cancer Center
Gideon Bollag, PhD
Plexxikon
Glenn Dranoff, MD
Dana-Farber Cancer Institute, Harvard Medical School
Carl June, MD, PhD
Abramson Family Cancer Research Institute, University of Pennsylvania
Edward Sausville, MD, PhD
Greenebaum Cancer Center, University of Maryland
Beverly Mitchell, MD
Stanford University
Garth Powis, D. Phil
University of Texas MD Anderson Cancer Center
Edward Sausville, MD, PhD
Greenebaum Cancer Center, University of Maryland
Neil Stahl, PhD
Regeneron Pharmaceuticals
Julian Adams, PhD
Infinity Pharmaceuticals
Michael Caligiuri, MD
Ohio State University Comprehensive Cancer Center
Kenneth Cowan, MD, PhD
University of Nebraska Medical Center Eppley Cancer Center
Jerry Collins, PhD
National Cancer Institute
Garth Powis, DPhil
University of Texas MD Anderson Cancer Center
Peter Senter, PhD
Seattle Genetics
Richard Van Etten, MD, PhD
Tufts-New England Medical Center Cancer Center
Roger M. Freidinger, PhD
Merck Research Laboratories
Robert C. Jackson, PhD
Cyclacel (UK)
Peter J. Houghton, PhD
St. Jude Children’s Research Hospital
Gregory L. Verdine, PhD
Dana-Farber Cancer Institute, Harvard Medical School
James Gibbons, PhD
Wyeth Pharmaceuticals
Robert C. Jackson, PhD
Cyclacel, (UK)
Lee Nadler, MD
Dana-Farber Cancer Institute
Eric Rowinsky, MD
ImClone Systems Incorporated
William Kaelin, MD
Dana-Farber Cancer Institute
Nicholas Lydon, PhD
Amgen
Edward Sausville, MD, PhD
Greenebaum Cancer Center, University of Maryland
Daniel Von Hoff, MD
Translational Genomics Institute (TGen)
Arizona Health Sciences Center’s Cancer Therapeutics Program
Christopher P. Austin, MD
National Institutes of Health
Elizabeth Eisenhauer, MD
National Cancer Institute of Canada
Donald W. Kufe, MD
Dana-Farber Cancer Institute
Nicholas Lydon, MD
Amgen
Ross C. Donehower, MD, FACP
Kimmel Cancer Center at Johns Hopkins Oncology Center
Allen Oliff, MD
GlaxoSmithKline Pharmaceuticals
Edward A. Sausville, MD, PhD
National Cancer Institute
Judith Sebolt-Leopold, PhD
Pfizer Global Research and Development